Febuxostat

Febuxostat Tablets (40mg, 80mg) is an oral non-purine selective inhibitor of xanthine oxidase on the WHO Model List of Essential Medicines. It achieves potent, durable inhibition by binding directly into the channel leading to the molybdenum pterin active center of both the oxidized and reduced forms of xanthine oxidase, with virtually zero inhibition of other enzymes involved in purine or pyrimidine metabolism. Unlike allopurinol, it is predominantly metabolized by hepatic glucuronidation and oxidation, requiring no dose adjustments in mild-to-moderate renal impairment. Indicated for chronic management of hyperuricemia in adult patients with gout who have had an inadequate response to or intolerance of allopurinol.

Febuxostat Tablets (40mg, 80mg) is an oral non-purine selective inhibitor of xanthine oxidase on the WHO Model List of Essential Medicines. It achieves potent, durable inhibition by binding directly into the channel leading to the molybdenum pterin active center of both the oxidized and reduced forms of xanthine oxidase, with virtually zero inhibition of other enzymes involved in purine or pyrimidine metabolism. Unlike allopurinol, it is predominantly metabolized by hepatic glucuronidation and oxidation, requiring no dose adjustments in mild-to-moderate renal impairment. Indicated for chronic management of hyperuricemia in adult patients with gout who have had an inadequate response to or intolerance of allopurinol.